ABBOTT MEDICAL is the applicant named in the FDA filings discussed here. The documented products include implantable pulse generators and their chargers for spinal cord stimulation and deep brain stimulation, plus the UltiSynq defibrillation lead and SurGrip suture sleeve accessory. The submission identifiers keep each product and change separate: several filings belong to existing PMA families, and each has its own recorded decision date and scope. [1][2][3][4][5]
Neuromodulation supplements decided in October 2026
The largest cluster in the public documents concerns spinal cord stimulation and deep brain stimulation hardware. P010032/S264 covers a Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger, received 2026-09-30 and decided 2026-10-30 under a 30-Day Notice, with the applicant's stated scope being qualification of an alternate MOSFET electronic component and supplier [2]. P010032/S266 covers the SCS IPG itself, received the same day and decided the same day, with a stated change from animal-derived to non-animal-derived EBS lubricant in TPU resin production for the Bluetooth low energy antenna [5].
On the DBS side, P140009/S144 covers the Deep Brain Stimulation (DBS) IPG with the same lubricant change and antenna scope, received 2026-09-30 and decided 2026-10-30 [3]. P140009/S142 covers the DBS IPG Charger with the alternate MOSFET qualification, same dates [4]. All four carry the Neurology advisory committee and product codes LGW or MHY. The stated reasons concern manufacturing processes and component suppliers. [2][3][4][5]
UltiSynq defibrillation lead approval
P950022/S153 covers the UltiSynq Defibrillation lead and SurGrip Suture Sleeve Accessory, product code LWS, Cardiovascular committee. The FDA record shows a Normal 180 Day Track supplement received 2026-04-23 and approved 2026-11-05, with supplement reason Change Design/Components/Specifications/Material [1]. The approval statement in the record names both the lead and the accessory [1].
Abbott’s product page describes UltiSynq’s ICD lead coil design. Its product page and technical PDF supply a manufacturer description of the lead; the FDA entry records the particular supplement and names the accessory. Those documents answer different research questions, so the product page should not replace the exact regulatory filing. [1][7][10]
What the filing record does and does not establish
The linked filings record submission and decision dates, supplement types, product codes, advisory committees and applicant-stated changes. The 49-record count is an as-of snapshot of filings linked by MedtechLedger and retrieved on November 20, 2026. It does not represent total company sales, the full device portfolio, market share or a measure of safety performance.
For research on these changes, begin with the exact supplement number. The charger filings identify a MOSFET component and supplier, while the generator filings concern an antenna manufacturing material. The charger and generator entries identify different changed items within their respective named product families. [2][3][4][5]
Identity and attribution boundaries
The FDA application field provides the legal applicant name for each cited submission. ABBOTT MEDICAL is the name used in these records. Sylmar and Plano addresses are recorded as filing contact details and are not labeled as corporate headquarters in these filings. Product descriptions for UltiSynq originate with Abbott’s cardiovascular product page and PDF. [1][2][7][10]



